Revive Therapeutics Ltd. (CNSX: RVV)
Health Care · Pharmaceuticals · CA
CA$0.03
+25.00% today · +66.7% 1Y
Revive Therapeutics Ltd. (CNSX: RVV) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $7.79M and employs 2 people.
Over the last twelve months the share price has gained 66.7%, trading between 0.01 and 0.08.
Tweenvest scores Revive Therapeutics Ltd. across four factors: quality 20/100, value 49/100. Its strongest factor is value.
RVV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.79M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -1.79
- 52-week high
- CA$0.08
- 52-week low
- CA$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 444.61M
- Employees
- 2
- Next earnings
- —
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.
- ISIN
- CA7615161030
- Listed since
- Jul 12, 2013
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vilin Bio Med LimitedNSEI: VILINBIO | $8.19M | Rs52.00 | -7.96% |
| Annexin Pharmaceuticals AB (publ)OM: ANNX | $7.92M | Skr9.08 | -0.87% |
| CNS Pharmaceuticals, Inc.NasdaqCM: CNSP | $7.82M | $5.35 | +0.47% |
| Shelter Pharma LimitedBSE: 543963 | $7.81M | Rs44.92 | +23.92% |
| Sunil Healthcare LimitedBSE: 537253 | $7.68M | Rs72.50 | +6.30% |
| Protect Pharmaceutical CorporationOTCPK: PRTT | $7.47M | $0.13 | -23.53% |
| Source Natural Foods and Herbal Supplements LimitedBSE: 531398 | $7.47M | Rs112.25 | +4.52% |
| Vineet Laboratories LimitedNSEI: VINEETLAB | $7.43M | Rs37.45 | +4.29% |
Figures last refreshed Oct 11, 2026.